JOHN KIRKWOOD to Polymorphism, Single Nucleotide
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Polymorphism, Single Nucleotide.
Connection Strength
0.641
-
Unfolding the mutational landscape of human melanoma. J Invest Dermatol. 2015 Mar; 135(3):659-662.
Score: 0.234
-
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108.
Score: 0.173
-
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy. Sci Rep. 2019 03 01; 9(1):3309.
Score: 0.077
-
A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon. PLoS One. 2014; 9(1):e86375.
Score: 0.054
-
Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma. J Immunother Cancer. 2026 Jun 19; 14(6).
Score: 0.032
-
Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanoma. Melanoma Res. 2026 Jun 01; 36(3):189-196.
Score: 0.031
-
A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
Score: 0.012
-
A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res. 2009 Sep 15; 69(18):7459-65.
Score: 0.010
-
Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk. PLoS One. 2008; 3(10):e3533.
Score: 0.009
-
Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. Cancer Res. 2005 Feb 01; 65(3):805-14.
Score: 0.007